
How McKinsey used its FDA connections to help opioid manufacturers: New congressional report
Following reports that McKinsey engaged in abusive and deceptive business practices to stoke the flames of the opioid epidemic, the House Oversight Committee on Wednesday released a new report documenting how the consulting company leveraged its work with the FDA to drive new business with opioid manufacturers.
Documents uncovered by the committee also show how opioid juggernaut Purdue Pharma explicitly tasked McKinsey with providing advice on how to influence the FDA’s decisions.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.